Agenus Inc. (AGEN)
| Market Cap | 1.24B |
| Revenue (ttm) | 68.55M |
| Net Income (ttm) | -225.94M |
| Shares Out | 222.91M |
| EPS (ttm) | -1.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,988,573 |
| Open | 5.57 |
| Previous Close | 5.50 |
| Day's Range | 5.28 - 5.57 |
| 52-Week Range | 2.50 - 6.79 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+88.3%) |
| Est. Earnings Date | Oct 28, 2021 |
About AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company als...
Financial Performance
In 2020, Agenus's revenue was $88.17 million, a decrease of -41.24% compared to the previous year's $150.05 million. Losses were -$180.91 million, 68.0% more than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for Agenus stock is "Strong Buy." The 12-month stock price forecast is 10.00, which is an increase of 88.32% from the latest price.
News
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispec...
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...
2 Stocks Set to Win From the Historic Malaria Vaccine Approval
But those wins probably won't be all that big.
Agenus to Present AGEN1181 Clinical Data at SITC
LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology ( ESMO21 ) Virtual Conference 2021. Related: Agenus Gains As Balstilim...
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
LEXINGTON, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines design...
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines Development of saponin molecules designed to provide high-efficacy and long-lasting p...
Balstilimab Monotherapy Data Published in Gynecologic Oncology
LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...
Hot Biotech Stocks That Deserve Your Attention In August 2021
Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
Why Agenus Fell by Over 4% on Monday
Investors were spooked by some ugly numbers in the company's latest earnings report.
Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Agenus Q2 Earnings
Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 32.14% over the past year to ($0.37), whic...
Agenus Corporate Update and Second Quarter 2021 Financial Report
LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines de...
Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission ...
Why Agenus Stock Sank on Tuesday
A top company executive is stepping down in the very near future.
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET
What Makes Agenus (AGEN) a Good Fit for "Trend Investing"
Agenus (AGEN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Re...
Agenus Acquires 120 Acres in the Heart of the California Biomanufacturing Center in Vacaville
VACAVILLE, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. has purchased 120-acres in Vacaville's California Biomanufacturing Center from housing developer A.G. Spanos, a transaction that represen...
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific...
LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adju...
Moving Average Crossover Alert: Agenus (AGEN)
Agenus (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Agenus (AGEN) Is a Great Choice for "Trend" Investors, Here's Why
Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our short...
Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
LEXINGTON, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designe...
Why Agenus Stock Is Marching Higher Today
The biotech took a major step toward becoming a commercial-stage cancer company.
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
The FDA has accepted for review Agenus Inc's (NASDAQ: AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer with disease progression on or after chemot...